HPLC paired with mass spectrometry or fluorescence detection can also resolve both species simultaneously within a single analytical run
According to the Summary of Product Characteristics (SmPCs), GLP-1 medications commonly cause nausea (reported in approximately 20-40% of patients with semaglutide and 12-21% with dulaglutide), vomiting, and diarrhoea, particularly during initial treatment and dose escalation
the deficiency of which is associated with the risk of contracting several diseases, notably cancer
Thyroid function, iron levels, and vitamin D status should all be evaluated
Glucagon-like peptide-1 (GLP-1) agonists work by enhancing insulin secretion and inhibiting glucagon release
Your dose is adjusted according to your response and tolerability, with ongoing physician guidance throughout treatment